MM Patients Remain Under Represented in Trials #ASH19
Roman Hajek, MD of University of Ostrava discusses MM patients remaining under represented in clinical trials based on standard laboratory parameters.
Related Articles
Everolimus Plus Lanreotide Shows Significant Benefits in New Standard in GEP-NET Treatment
Learn about the combination treatment of Everolimus Plus Lanreotide and its effectiveness for patients with advanced GEP-NETs.
BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Lead to Longevity Leaps?
Learn about the benefits of risk-reducing surgeries in young BRCA mutation carriers with a history of breast cancer.
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results
Get insights into the PATINA Phase 3 trial studying Palbociclib in ER+/HER2+ Metastatic Breast Cancer, and how it aims to improve outcomes in these patients.
Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?
Explore how CDK4/6 inhibitors are revolutionizing early breast cancer treatment. Find out about the expanded treatment scope and long-term efficacy.
ctDNA: ZEST Trial Cleans Up Breast Cancer Treatment – Niraparib (ZEJULA) vs. Placebo in High-Risk TNBC and BRCA-Mutated Patients
Findings from the ZEST trial highlight the potential of ctDNA surveillance in breast cancer management. Discover the role of Niraparib in enhancing disease-free survival.
ENHERTU® (Trastuzumab Deruxtecan, T-DXd) Outperforms Chemotherapy in Metastatic Breast Cancer: SABCS 2024 DESTINY-Breast06 Results
New data from DESTINY-Breast06 study presented at SABCS 2024. Explore efficacy of ENHERTU in hormone receptor-positive metastatic breast cancer patients.
EMBER-3 Reveal: Imlunestrant – Standalone Star or Team Player with Abemaciclib?
Get critical insights into advanced breast cancer treatment from the Phase 3 EMBER-3 trial. Explore the efficacy of Imlunestrant and its potential in improving patient…
FDA Approves Lazcluze Rybrevant Combo in Advanced NSCLC: Data Revealed
FDA approves combination treatment for advanced non-small cell lung cancer (NSCLC) targeting specific EGFR mutations. Learn about the MARIPOSA trial results,…
FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
FDA approved pembrolizumab (Keytruda) combined with chemotherapy for mesothelioma treatment. A new option for patients battling this aggressive disease.
SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
FDA approves Kisqali for early high-risk breast cancer treatment. Learn about this new treatment option and its benefits for patients.